French Teen in HIV Remission

An 18-year-old who was born with HIV but stopped taking antiretroviral drugs before she turned six has no detectable levels of the virus in her body.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Scanning electron micrograph of an HIV-infected H9 T cellIMAGE, NIAIDDoctors in France cannot detect any HIV in a woman who was born with the virus but was started on a cocktail of antiretroviral drugs from the time she was a few months old until she was about six. The 18-year-old has lived for about 12 years without taking any medication for HIV infection and does not have any of the genetic factors that make some people resistant to the virus. The physicians who have verified her more than decade-long remission presented data confirming the discovery at the International AIDS Society conference in Vancouver, Canada, on Monday (July 20). Because other children born with HIV and started on antiretrovirals soon after birth have shown similar therapeutic success only to later show signs of HIV's return, researchers are viewing this new case— the longest documented remission from HIV—with cautious optimism. “This girl is in remission,” Asier Sáez-Cirión, a researcher at the Pasteur Institute who examined the woman in Paris, told The Washington Post. “She’s not cured.”

“There have been other reports of treating infants followed by stoppage of antiretroviral therapy that have not turned out as well,” Scott Sieg at Case Western Reserve University in Cleveland, Ohio, told New Scientist. “This case provides new hope.”

The woman’s mother had HIV; after her birth, doctors gave the baby a prophylactic drug to prevent infection. But she was diagnosed with HIV when she was a month old. Shortly thereafter, she started antiretroviral therapy and continued until she was six, when her family took her off the drugs and ceased contacting her doctors. After six months of no medical treatment, this year her doctors could not detect the virus in her body.

The case illustrates the growing consensus that aggressively treating patients with antiretroviral ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies